• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

布拉氏酵母菌 CNCM I-745 与多菌株芽孢杆菌 clausii 益生菌治疗儿童急性肠胃炎的随机、直接比较研究。

Randomized, direct comparison study of Saccharomyces boulardii CNCM I-745 versus multi-strained Bacillus clausii probiotics for the treatment of pediatric acute gastroenteritis.

机构信息

Consultorio de Pediatria Maza, Buenos Aires, Argentina.

Grupo Pediatrico Belgrano, Buenos Aires, Argentina.

出版信息

Medicine (Baltimore). 2022 Sep 9;101(36):e30500. doi: 10.1097/MD.0000000000030500.

DOI:10.1097/MD.0000000000030500
PMID:36086703
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9646502/
Abstract

BACKGROUND

The choice of an appropriate probiotic for pediatric acute gastroenteritis (PAGE) can be confusing. Our aim was to compare the efficacy and safety of 2 probiotics (Saccharomyces boulardii CNCM I-745 vs a 4-strain mixture of Bacillus clausii O/C, SIN, N/R, T) for the treatment of PAGE.

METHODS

A 2-arm parallel, randomized trial recruited children (6 months to 5 years old) with mild-moderate acute diarrhea, from 8 centers in Argentina. A total of 317 children were enrolled and blindly randomized to 5 days of either S boulardii CNCM I-745 (n = 159) or a 4-strain mixture of B clausii (n = 158), then followed for 7 days post-probiotic treatment. A stool sample was collected at inclusion for pathogen identification. The primary outcome was duration of diarrhea defined as the time from enrollment to the last loose stool followed by the first 24-hour period with stool consistency improvement. Secondary outcomes included frequency of loose stools/day, severity of diarrhea, number reporting no diarrhea at Day 6, time-to-first formed stool, recurrence of diarrhea by study end (Day 12) and safety outcomes.

RESULTS

Three hundred twelve (98%) children completed the study. S boulardii CNCM I-745 showed a significant reduction (P = .04) in the mean duration of diarrhea (64.6 hours, 95% confidence interval [CI] 56.5-72.8) compared to those given B clausii (78.0 hours, 95% CI 69.9-86.1). Both probiotics showed improvement in secondary outcomes and were well-tolerated.

CONCLUSION

In this study, S boulardii CNCM I-745 demonstrated better efficacy than B clausii mix for reducing the duration of pediatric acute diarrhea.

摘要

背景

对于儿科急性肠胃炎(PAGE),选择合适的益生菌可能会令人困惑。我们的目的是比较 2 种益生菌(布拉氏酵母菌 CNCM I-745 与由 4 株芽孢杆菌组成的混合菌,即 B. clausii O/C、SIN、N/R 和 T)治疗 PAGE 的疗效和安全性。

方法

这是一项双臂平行、随机试验,共招募了 8 家阿根廷中心的 317 名 6 个月至 5 岁患有轻度至中度急性腹泻的儿童。所有儿童均接受 5 天的布拉氏酵母菌 CNCM I-745(n=159)或 4 株芽孢杆菌混合菌(n=158)治疗,然后在益生菌治疗后随访 7 天。在纳入时采集粪便样本进行病原体鉴定。主要结局是腹泻持续时间,定义为从入组到最后一次稀便后首次出现 24 小时粪便稠度改善的时间。次要结局包括每日稀便次数、腹泻严重程度、第 6 天无腹泻报告的比例、首次成型粪便的时间、研究结束时(第 12 天)腹泻复发率以及安全性结局。

结果

312 名(98%)儿童完成了研究。与给予 B. clausii 混合菌的儿童相比,布拉氏酵母菌 CNCM I-745 组腹泻持续时间的平均(64.6 小时,95%置信区间[CI] 56.5-72.8)显著缩短(P=0.04)。两种益生菌均改善了次要结局,且耐受性良好。

结论

在这项研究中,与 B. clausii 混合菌相比,布拉氏酵母菌 CNCM I-745 可更有效地缩短儿科急性腹泻的持续时间。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526c/9646502/1fc6b344b88a/medi-101-e30500-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526c/9646502/caadd8b93e8b/medi-101-e30500-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526c/9646502/cd434d20e59d/medi-101-e30500-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526c/9646502/1fc6b344b88a/medi-101-e30500-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526c/9646502/caadd8b93e8b/medi-101-e30500-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526c/9646502/cd434d20e59d/medi-101-e30500-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526c/9646502/1fc6b344b88a/medi-101-e30500-g003.jpg

相似文献

1
Randomized, direct comparison study of Saccharomyces boulardii CNCM I-745 versus multi-strained Bacillus clausii probiotics for the treatment of pediatric acute gastroenteritis.布拉氏酵母菌 CNCM I-745 与多菌株芽孢杆菌 clausii 益生菌治疗儿童急性肠胃炎的随机、直接比较研究。
Medicine (Baltimore). 2022 Sep 9;101(36):e30500. doi: 10.1097/MD.0000000000030500.
2
[Efficacy of CNCM I-745 probiotic drug in the prevention and treatment of diarrhea in hospitalized patients with new coronavirus infection COVID-19].[法国国家微生物资源保藏中心(CNCM)I-745益生菌药物在预防和治疗新型冠状病毒感染(COVID-19)住院患者腹泻中的疗效]
Ter Arkh. 2022 Nov 22;94(10):1163-1170. doi: 10.26442/00403660.2022.10.201881.
3
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Saccharomyces boulardii in Infants and Children With Acute Diarrhea.布拉氏酵母菌散剂治疗婴幼儿急性腹泻的多中心、随机、双盲、安慰剂对照临床研究
Pediatr Infect Dis J. 2020 Nov;39(11):e347-e351. doi: 10.1097/INF.0000000000002849.
4
Specific Probiotics for the Treatment of Pediatric Acute Gastroenteritis in India: A Systematic Review and Meta-Analysis.印度用于治疗小儿急性肠胃炎的特定益生菌:一项系统评价与荟萃分析
JPGN Rep. 2021 May 27;2(3):e079. doi: 10.1097/PG9.0000000000000079. eCollection 2021 Aug.
5
Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.酵母益生菌布拉酵母菌CNCM I-745的独特特性:一篇叙述性综述。
Cureus. 2023 Oct 1;15(10):e46314. doi: 10.7759/cureus.46314. eCollection 2023 Oct.
6
Effect of CNCM-I 3799 and CU-1 on Acute Watery Diarrhea: A Randomized Double-Blind Placebo-Controlled Study in Indian Children.法国国家微生物资源保藏中心菌株I 3799和CU-1对急性水样腹泻的影响:一项针对印度儿童的随机双盲安慰剂对照研究
Pediatr Gastroenterol Hepatol Nutr. 2021 Sep;24(5):423-431. doi: 10.5223/pghn.2021.24.5.423. Epub 2021 Sep 8.
7
Efficacy and safety of Bacillus clausii (O/C, N/R, SIN, T) probiotic combined with oral rehydration therapy (ORT) and zinc in acute diarrhea in children: a randomized, double-blind, placebo-controlled study in India.克劳氏芽孢杆菌(O/C、N/R、SIN、T)益生菌联合口服补液疗法(ORT)及锌治疗儿童急性腹泻的疗效与安全性:印度一项随机、双盲、安慰剂对照研究
Trop Dis Travel Med Vaccines. 2022 Apr 10;8(1):9. doi: 10.1186/s40794-022-00166-6.
8
Effectiveness and Safety of Saccharomyces Boulardii for the Treatment of Acute Gastroenteritis in the Pediatric Population: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.布拉氏酵母菌散剂治疗儿科急性胃肠炎的有效性和安全性:系统评价和随机对照试验的荟萃分析。
Comput Math Methods Med. 2022 Sep 20;2022:6234858. doi: 10.1155/2022/6234858. eCollection 2022.
9
Bacillus clausii UBBC-07 reduces severity of diarrhoea in children under 5 years of age: a double blind placebo controlled study.芽孢杆菌 UBBC-07 降低 5 岁以下儿童腹泻严重程度的双盲安慰剂对照研究。
Benef Microbes. 2019 Mar 13;10(2):149-154. doi: 10.3920/BM2018.0094. Epub 2019 Jan 14.
10
as adjunctive treatment for acute community-acquired diarrhea among Filipino children: a large-scale, multicenter, open-label study (CODDLE).作为菲律宾儿童急性社区获得性腹泻的辅助治疗:一项大规模、多中心、开放标签研究(CODDLE)。
Trop Dis Travel Med Vaccines. 2019 Jul 23;5:14. doi: 10.1186/s40794-019-0089-5. eCollection 2019.

引用本文的文献

1
Efficacy and safety of CNCM I-745 for the treatment of pediatric acute diarrhea in China: a systematic review and meta-analysis.中国国家微生物资源库I-745治疗小儿急性腹泻的疗效和安全性:一项系统评价与Meta分析
Front Cell Infect Microbiol. 2025 Jun 4;15:1587792. doi: 10.3389/fcimb.2025.1587792. eCollection 2025.
2
Efficacy of probiotics for treatment of acute or persistent diarrhoea in children from birth till 10 years: Systematic review and meta-analysis.益生菌对出生至10岁儿童急性或持续性腹泻的治疗效果:系统评价与荟萃分析。
J Glob Health. 2024 Dec 20;14:04236. doi: 10.7189/jogh.14.04236.
3
LRa05 in the treatment of acute diarrhea in children: a randomized controlled trial.

本文引用的文献

1
Specific Probiotics for the Treatment of Pediatric Acute Gastroenteritis in India: A Systematic Review and Meta-Analysis.印度用于治疗小儿急性肠胃炎的特定益生菌:一项系统评价与荟萃分析
JPGN Rep. 2021 May 27;2(3):e079. doi: 10.1097/PG9.0000000000000079. eCollection 2021 Aug.
2
Which Probiotic Is the Most Effective for Treating Acute Diarrhea in Children? A Bayesian Network Meta-Analysis of Randomized Controlled Trials.哪种益生菌对治疗儿童急性腹泻最有效?一项基于随机对照试验的贝叶斯网状Meta 分析。
Nutrients. 2021 Nov 29;13(12):4319. doi: 10.3390/nu13124319.
3
Gut Microbiota in Mexican Children With Acute Diarrhea: An Observational Study.
LRa05治疗儿童急性腹泻:一项随机对照试验
Front Nutr. 2024 Nov 15;11:1479186. doi: 10.3389/fnut.2024.1479186. eCollection 2024.
4
Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.酵母益生菌布拉酵母菌CNCM I-745的独特特性:一篇叙述性综述。
Cureus. 2023 Oct 1;15(10):e46314. doi: 10.7759/cureus.46314. eCollection 2023 Oct.
5
Effect of the Probiotic DE-CA9 on Fecal Scores, Serum Oxidative Stress Markers and Fecal and Serum Metabolome in Healthy Dogs.益生菌DE-CA9对健康犬粪便评分、血清氧化应激标志物以及粪便和血清代谢组的影响。
Vet Sci. 2023 Sep 11;10(9):566. doi: 10.3390/vetsci10090566.
墨西哥急性腹泻儿童的肠道微生物群:一项观察性研究。
Pediatr Infect Dis J. 2021 Aug 1;40(8):704-709. doi: 10.1097/INF.0000000000003128.
4
Probiotics in Pediatrics. A Review and Practical Guide.《儿科学中的益生菌。综述与实用指南》
Nutrients. 2021 Jun 24;13(7):2176. doi: 10.3390/nu13072176.
5
Probiotics for treating acute infectious diarrhoea.益生菌治疗急性感染性腹泻。
Cochrane Database Syst Rev. 2020 Dec 8;12(12):CD003048. doi: 10.1002/14651858.CD003048.pub4.
6
: What Makes It Tick as Successful Probiotic?是什么使其成为成功的益生菌?
J Fungi (Basel). 2020 Jun 4;6(2):78. doi: 10.3390/jof6020078.
7
Use of Probiotics for the Management of Acute Gastroenteritis in Children: An Update.益生菌用于儿童急性胃肠炎管理的最新进展
J Pediatr Gastroenterol Nutr. 2020 Aug;71(2):261-269. doi: 10.1097/MPG.0000000000002751.
8
Acute Gastroenteritis in Children of the World: What Needs to Be Done?世界范围内儿童急性胃肠炎:该做些什么?
J Pediatr Gastroenterol Nutr. 2020 May;70(5):694-701. doi: 10.1097/MPG.0000000000002669.
9
Systematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children-a 2020 update.系统评价与荟萃分析:布拉氏酵母菌治疗儿童急性胃肠炎-2020 年更新。
Aliment Pharmacol Ther. 2020 Apr;51(7):678-688. doi: 10.1111/apt.15659. Epub 2020 Feb 13.
10
Microbiome Composition in Pediatric Populations from Birth to Adolescence: Impact of Diet and Prebiotic and Probiotic Interventions.儿科人群从出生到青春期的微生物组组成:饮食以及益生元和益生菌干预的影响。
Dig Dis Sci. 2020 Mar;65(3):706-722. doi: 10.1007/s10620-020-06092-x.